Building upon MFN Summit 1.0 to create sustainable launch, access and pricing strategies
London UK – 26 August 2026 – Partners4Access (P4A) announced the MFN Access Summit 2026, an in-person, full-day workshop dedicated to most-favoured-nation (MFN) pricing. The MFN Access Summit takes place on Tuesday, 15 September 2026, at Hinxton Hall, Cambridge, UK after a successful MFN Summit held in Zug, Switzerland in April this year.
“The MFN Access Summit was a fantastic occasion to learn, connect with peers and friends and, most importantly, think creatively about some of the main challenges facing our industry with a solutions-based approach”
Market Access Lead, Attendee
MFN-style pricing and new international reference pricing (IRP) and Centres for Medicare & Medicaid Services (CMS) models are reshaping how global payers set expectations for launch prices, discounts, and access. Traditional IRP playbooks are no longer sufficient when a single “lowest price” in a company’s international basket can materially affect global revenues. The MFN Access Summit 2026 has been designed by P4A to help pharmaceutical companies get ahead of this shift before it dictates their pricing strategy for them.
| Event | P4A Access Summit 2026 “Most-Favoured-Nation in Practice” |
| Organiser | Partners4Access (P4A) |
| Date | Tuesday, 15 September 2026 |
| Location | Hinxton Hall, Cambridge, UK |
| Format | In-person, full-day workshop with cross-functional breakout sessions |
| Focus | MFN, IRA-style measures, CMS models and IRP for pharmaceutical launch, access and pricing |
| Registration | partners4access.com/insights/p4a-access-summit-2026 |
Why Attend
✔ Protect your revenue before MFN does it for you. Understand how emerging MFN and international MFN constructs interact with IRA-style measures, and IRP – and what that means for your brands’ list and net prices.
✔ Turn MFN into a competitive advantage. Pressure-test your launch sequencing, access, and contracting strategies against realistic MFN scenarios that competitors may not yet be planning for.
✔ Leave with a concrete action plan, not just slides. Work in cross-functional teams on your own assets to build an “MFN-proof” pricing and access plan you can take straight into brand and governance discussions.
Who Should Attend
- Global and regional market access and pricing team members working on pharmaceutical launches or major renegotiations.
- Commercial and brand leads for high-value or high-visibility assets.
- HEOR, policy, and finance stakeholders involved in price-setting, deal evaluation, and scenario planning.
What You Will Do on the Day
- Decode the latest MFN and international pricing developments in the U.S. and key reference markets and understand their likely trajectory.
- Map MFN/IRP exposure and stress-test launch and pricing strategies under three future states.
- Design practical contracting and value-evidence responses that minimise MFN “price drag” while sustaining competitive positioning.
“MFN is already shaping launch and pricing decisions being made today. Our goal with this Summit is to give market access and pricing teams a pragmatic framework to build MFN-proof strategies now, rather than react to them later. Ultimately, leveraging MFN as a source of competitive advantage, not purely an area of concern.”
Sophie Schmitz, Managing Partner at P4A.
Frequently Asked Questions
What is the P4A MFN Access Summit 2026?
The MFN Access Summit 2026 is an in-person, full-day workshop hosted by P4A on most-favoured-nation (MFN) pricing, titled “Most-Favoured-Nation in Practice: Building MFN-proof Launch, Access and Pricing Strategies for 2026 and Beyond.”
Who is organising the MFN conference in Cambridge, UK?
Partners4Access (P4A), a global rare disease market access consultancy specialising in orphan drugs, cell and gene therapies, and complex access challenges, is organising and hosting the event.
When and where does the event take place?
The MFN Access Summit 2026 takes place on Tuesday, 15 September 2026, at Hinxton Hall, Cambridge, UK.
Who should attend the P4A MFN summit?
The Summit is designed for global and regional market access and pricing professionals, commercial and brand leads for high-value assets, and HEOR, policy, and finance stakeholders involved in price-setting and scenario planning.
About Partners4Access
P4A is a specialized global consultancy focused on providing market access, pricing, reimbursement and digital solutions for orphan drugs, cell and gene therapies, and other complex access challenges. With a mission to improve patient access to life-changing therapies, P4A works closely with pharmaceutical and biotech companies to navigate the complex landscape of rare diseases, ensuring successful market entry and sustainable patient access.
Acronyms:
CMS – Centres for Medicare & Medicaid Services
HEOR – Health Economics & Outcomes Research
IRA – Inflation Reduction Act
IRP – International Price Referencing
MFN – Most Favoured Nation
P4A – Partners4Access
Media Contact
Georgie Rack
Chief Operating Officer, Partners4Access
[email protected]
Tel: +44 7854 941615
